Drug-Induced Inhibition of Platelet Function Delays Progression of Peripheral Occlusive Arterial Disease

Hess, H; Mietaschk, A; Deichsel, Guntram

doi:10.1016/s0140-6736(85)91144-4

Cited by 241 publications

(62 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A final number of 11 trials reporting outcomes in patients with PDV were included in the analysis [10,[21][22][23][24][25][26][27][28][29][30] (Fig 1).…”

Section: Studies Includedmentioning

confidence: 99%

“…The Critical Leg Ischaemia Prevention Study (CLIPS) trial randomized patients to aspirin versus placebo and aspirin plus vitamin E versus vitamin E only, while the Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial randomized patients to aspirin versus placebo and aspirin plus antioxidant versus antioxidant only [21,22]. Three trials had multiple comparison arms and thus only the aspirin and placebo arms were included [23,25,26]. Three trials were multicenter and reported outcomes exclusively in patients without prior history of an ischemic event (including prior stroke or MI) [10,21,22], and 4 trials included low-dose aspirin ( 325mg per day) [10,21,22,24].…”

Section: Studies Includedmentioning

confidence: 99%

“…Nine trials reported the outcome of all-cause mortality [10,[21][22][23][24][27][28][29][30]. At a weighted mean follow up duration of 6.1 (SD = 2.9) years, the incidence of all-cause mortality was similar in both the aspirin and control groups, 7.7% (95% CI 4.3-11.1%) versus 8.5% (95% CI 4.6-12.5%) (RR = 0.93, 95% CI 0.8-1.1, P = 0.33, I 2 = 0%) (Fig 2).…”

Section: Primary Efficacy Outcomementioning

confidence: 99%

“…At a weighted mean follow up of 6.2 (SD = 2.9) years the incidence of MI was similar in both the aspirin and control groups, 3.6% (95% CI 1.63-5.5%) versus 5.5% (95% CI 3.15-7.86%), respectively; RR = 0.91, 95% CI 0.67-1.23, P = 0.54, I 2 = 16%. Stroke was reported by 7 trials with a weighted mean follow up duration of 6.2 (SD = 2.9) years [10,[21][22][23][28][29][30]. The incidence of stroke was 3.2% (95% CI 1.3-5.1%) in the aspirin group versus 4% (95% CI 2.0-6.0%) in the control group (RR = 0.72, 95% CI 0.43-1.22, P = 0.22, I 2 = 45%).…”

Section: Secondary Efficacy Outcomesmentioning

confidence: 99%

“…The incidence of stroke was 3.2% (95% CI 1.3-5.1%) in the aspirin group versus 4% (95% CI 2.0-6.0%) in the control group (RR = 0.72, 95% CI 0.43-1.22, P = 0.22, I 2 = 45%). MACCE was reported by 9 trials at a weighted mean follow up duration of 6.1 (SD = 2.9) years [10,[21][22][23][24][28][29][30]. The incidence of MACCE was similar between both groups, 9.3% (95% CI 4.8-13.9%) versus 11.6% (95% CI 7.2-16.0%), respectively, (RR = 1.0, 95% CI 0.83-1.20, P = 0.96, I 2 = 16%) (Fig 3).…”

Section: Secondary Efficacy Outcomesmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Mahmoud

Elgendy

Rambarat

et al. 2017

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…A final number of 11 trials reporting outcomes in patients with PDV were included in the analysis [10,[21][22][23][24][25][26][27][28][29][30] (Fig 1).…”

Section: Studies Includedmentioning

confidence: 99%

Section: Studies Includedmentioning

confidence: 99%

Section: Primary Efficacy Outcomementioning

confidence: 99%

Section: Secondary Efficacy Outcomesmentioning

confidence: 99%

Section: Secondary Efficacy Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Mahmoud

Elgendy

Rambarat

et al. 2017

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

Dipyridamole Plus Aspirin in Cerebrovascular Disease

Wilterdink

Easton

1999

Arch Neurol

View full text Add to dashboard Cite

The ESPS-2 showed that dipyridamole alone prevents stroke. More importantly, it showed a substantial benefit for dipyridamole combined with aspirin over aspirin alone. When the ESPS-2 data are aggregated with the 14 previous trials of dipyridamole combined with aspirin over aspirin alone, the combination reduces the risk of stroke by 23% over aspirin alone. Nevertheless, important questions remain unanswered. We conclude that another randomized clinical trial showing a significant benefit of the combination of dipyridamole plus aspirin over aspirin alone may be needed before the addition of dipyridamole to aspirin is widely accepted for prevention of stroke.

show abstract

The Relationship of Depression to Cardiovascular Disease

Musselman¹,

Evans²,

Nemeroff³

1998

Arch Gen Psychiatry

1,384

782

View full text Add to dashboard Cite

This article reviews the burgeoning literature on the relationship of mood disorders and heart disease. Major depression and depressive symptoms, although commonly encountered in medical populations, are frequently underdiagnosed and undertreated in patients with cardiovascular disease (CVD). This is of particular importance because several studies have shown depression and its associated symptoms to be a major risk factor for both the development of CVD and death after an index myocardial infarction. This review of the extant literature is derived from MEDLINE searches (1966-1997) using the search terms "major depression," "psychiatry," "cardiovascular disease," and "pathophysiology." Studies investigating pathophysiological alterations related to CVD in depressed patients are reviewed. The few studies on treatment of depression in patients with CVD are also described. Treatment of depression in patients with CVD improves their dysphoria and other signs and symptoms of depression, improves quality of life, and perhaps even increases longevity. Recommendations for future research are proposed.

show abstract

Drug-Induced Inhibition of Platelet Function Delays Progression of Peripheral Occlusive Arterial Disease

Cited by 241 publications

References 13 publications

Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Dipyridamole Plus Aspirin in Cerebrovascular Disease

The Relationship of Depression to Cardiovascular Disease

Contact Info

Product

Resources

About